NASDAQ:HSIC - Henry Schein Stock Price, Price Target & More

Henry Schein trades on the NASDAQ under the ticker symbol "HSIC."

Shares of Henry Schein split before market open on Friday, September 15th 2017. The 2-1 split was announced on Wednesday, August 16th 2017. The newly issued shares were payable to shareholders after the market closes on Thursday, September 14th 2017. An investor that had 100 shares of Henry Schein stock prior to the split would have 200 shares after the split.

Henry Schein declared that its Board of Directors has authorized a share repurchase program on Tuesday, September 19th 2017, which permits the company to repurchase $400,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to repurchase up to 6.3% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company's management believes its shares are undervalued.

Henry Schein, Inc. (NASDAQ:HSIC) announced its earnings results on Tuesday, May, 8th. The company reported $0.95 EPS for the quarter, beating the consensus estimate of $0.92 by $0.03. The company earned $3.22 billion during the quarter, compared to analyst estimates of $3.18 billion. Henry Schein had a net margin of 3.18% and a return on equity of 19.68%. The business's revenue for the quarter was up 10.2% on a year-over-year basis. During the same period in the prior year, the business posted $0.88 EPS. View Henry Schein's Earnings History.

Henry Schein is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Henry Schein.

Henry Schein issued an update on its FY18 earnings guidance on Tuesday, May, 8th. The company provided earnings per share (EPS) guidance of $4.03-4.14 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.09.

19 equities research analysts have issued 1-year price targets for Henry Schein's stock. Their forecasts range from $73.00 to $102.00. On average, they expect Henry Schein's stock price to reach $81.50 in the next year. This suggests a possible upside of 10.8% from the stock's current price. View Analyst Ratings for Henry Schein.

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Henry Schein in the last year. There are currently 1 sell rating, 9 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold."

Some companies that are related to Henry Schein include Express Scripts (ESRX), Illumina (ILMN), FRESENIUS SE &/S (FSNUY), Humana (HUM), Zoetis (ZTS), BEXIMCO PHARMAC/S GDR REGS (BXP), Baxter International (BAX), Regeneron Pharmaceuticals (REGN), HCA Healthcare (HCA), Takeda Pharmaceutical (TKPYY), ESSILOR Intl S/S (ESLOY), ASTELLAS PHARMA/ADR (ALPMY), Edwards Lifesciences (EW), Fresenius Medical Care AG & Co. (FMS) and Alexion Pharmaceuticals (ALXN).

News headlines about HSIC stock have trended somewhat positive this week, according to Accern Sentiment. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Henry Schein earned a news sentiment score of 0.11 on Accern's scale. They also assigned news headlines about the company an impact score of 44.72 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Henry Schein's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Swedbank (1.33%), Fenimore Asset Management Inc. (0.36%), Riverbridge Partners LLC (0.27%), Bank of Montreal Can (0.24%), Port Capital LLC (0.14%) and Fisher Asset Management LLC (0.07%). Company insiders that own Henry Schein stock include Barry J Alperin, Donald J Kabat, Gerald A Benjamin, James A Harding, Kurt P Kuehn, Lorelei Mcglynn, Mark E Mlotek, Michael Racioppi, Michael S Ettinger, Paul Brons, Paul Rose, Philip A Laskawy and Steven Paladino. View Institutional Ownership Trends for Henry Schein.

HSIC stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Swedbank, Bank of Montreal Can, Neville Rodie & Shaw Inc., Riverbridge Partners LLC, Gateway Investment Advisers LLC, Carderock Capital Management Inc. and Laurel Grove Capital LLC. Company insiders that have sold Henry Schein company stock in the last year include Barry J Alperin, Mark E Mlotek, Paul Brons and Paul Rose. View Insider Buying and Selling for Henry Schein.

HSIC stock was acquired by a variety of institutional investors in the last quarter, including Addenda Capital Inc., Xact Kapitalforvaltning AB, Port Capital LLC, Addenda Capital Inc., State of Alaska Department of Revenue, Trust Co. of Oklahoma, DnB Asset Management AS and IFM Investors Pty Ltd. View Insider Buying and Selling for Henry Schein.

Shares of HSIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of HSIC stock can currently be purchased for approximately $73.58.

Henry Schein has a market capitalization of $11.41 billion and generates $12.46 billion in revenue each year. The company earns $406.29 million in net income (profit) each year or $3.60 on an earnings per share basis. Henry Schein employs 22,000 workers across the globe.

Henry Schein's mailing address is 135 DURYEA RD, MELVILLE NY, 11747. The company can be reached via phone at 631-843-5500 or via email at [email protected]